ST. PETERSBURG, Fla., July 1, 2026
ARTAN Bio has announced the successful completion of a $1 million seed financing round to accelerate development of its mutation-specific transfer RNA (tRNA) platform toward first-in-human clinical studies. The investment, led by company co-founder Michael Torres, Ph.D., follows his leadership in building CrossBridge Bio through its acquisition by Eli Lilly and marks an important milestone for the longevity-focused biotechnology company. The funding will support IND-enabling studies, manufacturing scale-up, and regulatory preparation for ARTAN Bio’s proprietary engineered suppressor tRNA platform, which is designed to restore protein production in cells affected by disease-causing nonsense mutations. Alongside the financing, the company also announced a leadership transition with Brian Bodemann appointed as Chief Executive Officer, while co-founder Anthony Schwartz, Ph.D. assumes the role of Chief Operating Officer to oversee operational and scientific execution. Together, these developments position ARTAN Bio to advance its innovative programmable genetic medicine platform toward clinical translation while expanding opportunities in genetic diseases and aging-related disorders.
Seed Investment Accelerates First-in-Human Development
The newly secured $1 million seed round provides ARTAN Bio with critical resources to transition its mutation-specific codon suppression technology from laboratory research into clinical development. The company’s proprietary platform is built around engineered suppressor transfer RNAs (tRNAs) designed to overcome nonsense mutations, genetic alterations that introduce premature stop codons during protein synthesis and prevent cells from producing functional proteins. These mutations contribute to numerous rare genetic disorders as well as several aging-related diseases, creating significant unmet medical needs across multiple therapeutic areas.
The new financing will primarily support Investigational New Drug (IND)-enabling studies, manufacturing process optimization, regulatory planning, and preparation for future human clinical trials. By targeting disease at the underlying genetic mutation rather than treating downstream symptoms, ARTAN Bio aims to develop a highly programmable therapeutic platform capable of addressing a broad range of previously difficult-to-treat conditions.
Leadership Expansion Supports Clinical Growth Strategy
Advertisement
As part of the company’s next phase of development, Brian Bodemann has been appointed Chief Executive Officer, bringing extensive scientific and commercial leadership experience to guide ARTAN Bio through clinical development and strategic partnerships. Co-founder Anthony Schwartz, Ph.D., transitions to the role of Chief Operating Officer, where he will focus on advancing research operations, manufacturing readiness, and translational development activities.
Meanwhile, co-founder Michael Torres, Ph.D., continues serving as Chief Scientific Officer, leveraging his experience from the successful development and acquisition of CrossBridge Bio to help shape ARTAN Bio’s long-term scientific strategy. Company leadership believes the strengthened executive team combines expertise in genetics, biotechnology commercialization, and translational medicine, positioning ARTAN Bio to effectively advance its platform from preclinical research into clinical evaluation while pursuing future collaborations within the biotechnology industry.
Programmable tRNA Technology Targets Genetic and Aging Diseases
ARTAN Bio’s platform represents a novel approach to precision genetic medicine by utilizing programmable suppressor tRNAs to restore normal protein translation in cells carrying nonsense mutations. Instead of replacing genes or permanently editing DNA, the technology aims to bypass premature stop signals during protein synthesis, allowing cells to produce functional proteins naturally. This mechanism has potential applications across a broad spectrum of rare inherited disorders, age-related diseases, and other conditions driven by defective protein production.
The company believes its platform could establish a new class of programmable therapeutics capable of treating multiple diseases through a common molecular mechanism. Headquartered within spARK Labs by ARK Invest, ARTAN Bio continues advancing innovation at the intersection of longevity science, genetic medicine, and programmable RNA therapeutics. With fresh capital, expanded leadership, and a clear clinical development strategy, the company is positioning itself to become a key innovator in the emerging field of tRNA-based precision medicine.
Source: ARTAN Bio press release
